C反应蛋白和胸腔积液在急性胰腺炎早期预后评估中的价值

目的 探讨C反应蛋白(CRP)和胸腔积液在急性胰腺炎（acute pancreatitis,AP）早期诊断及预后评估中的价值。方法 回顾性的分析2008年10月至2010年10月，安徽医科大学第二附属医院确诊为急性胰腺炎且入院时发病在24h以内、临床资料完整的住院患者89例，依据2003年中华医学会消化病学分会胰腺病学组制定的“中国急性胰腺炎诊治指南”，分为轻症急性胰腺炎(mild acute panereatitis,MAP)组和重症急性胰腺炎(severe acute pancreatitis，SAP)组，两组资料具有可比性，在第1，2，3，7天检测C反应蛋白(C-reactive protein，CRP)水平及入院时有无胸腔积液。并对结果进行对照分析。结果 同时期SAP组与MAP组相比CRP质量浓度差异具有统计学意义（P＜0.05），对CRP升高（CRP≥150 mg/L）、胸腔积液和两者同时存在这三项参数分别进行相对危险度分析，发现三者均可作为SAP的独立预测指标，其中CRP升高联合胸腔积液预测SAP最为准确，相对危险度RR为4.8，阳性预测值为100％。结论CRP和胸腔积液是一种有用的、简单的、经济的指标，有助于在急性胰腺炎早期对其严重程度作出预测。

The roles of C-reactive protein and pleural effusion in prognosis evaluation in the early stage of acute pancreatitis

Objective To investigate the values of C-reactive protein (CRP) and pleural effusion in predicting the severity in the early stage of severe acute pancreatitis (SAP) . Methods A total of 89patients with acute pancreatitis were collected from October 2008 through October 2010 for retrospective analysis. Patients were divided into two groups, namely mild acute pancreatitis (MAP) group and SAP group as per the Guidelines for Clinical Diagnosis and Classification of Acute Pancreatitis set by the Society of Chinese Medical Association in 2003. The levels of CRP were measured on the 1st, 2nd, 3rd and 7th days after admission. Pleural effusion was also observed on the 1 st day after admission. The data of two groups were analyzed and compared. Results There were significant differences in CRP at all intervals between SAP group and MAP group (P ＜0.05) . The relative risk of increase in CRP ( ＞ 150 mg/L),pleural effusion and increase in CRP along with pleural effusion were analyzed, and each of these three markers can be used as an independent severity factor of SAP. Particularly, increase in CRP along with pleural effusion could be most sensitive in predicting the severity of SAP with relative risk (RR) to be 4. 8 and specificity of predictive value to be 100％. Conclusions C-reactive protein and pleural effusion are available, simple and economic biomarkers which can help us predict the risk of acute pancreatitis in the early stage.